References:
1. Piaścik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J, Gabryelewicz A. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. PANCREAS 2010; 39: 863-67.
2. UK W, Association OUGS, Working POTB, Association OSOG, Pancreatic SOGB, UK WPOA. UK guidelines for the management of acute pancreatitis. GUT 2005; 54: i1-09.
3. Mofidi R, Madhavan KK, Garden OJ, Parks RW. An audit of the management of patients with acute pancreatitis against national standards of practice. BRIT J SURG 2007; 94: 844-48.
4. Isaji S, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, Kimura Y, Takeda K, Koizumi M, Otsuki M, Matsuno S, JPN. JPN Guidelines for the management of acute pancreatitis:surgical management. Journal of Hepato-Biliary-Pancreatic Surgery 2006; 13: 48-55.
5. Xue P, Deng LH, Xia Q, Zhang ZD, Hu WM, Yang XN, Song B, Huang ZW. Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage. World J Gastroenterol 2008; 14: 474-78.
6. Beger HG, Rau B, Mayer J, Pralle U. Natural course of acute pancreatitis. WORLD J SURG 1997; 21: 130-35.
7. Leppaniemi A, Tolonen M, Tarasconi A, Segovia-Lohse H, Gamberini E, Kirkpatrick AW, Ball CG, Parry N, Sartelli M, Wolbrink D, van Goor H, Baiocchi G, Ansaloni L, Biffl W, Coccolini F, Di Saverio S, Kluger Y, Moore E, Catena F. 2019 WSES guidelines for the management of severe acute pancreatitis. WORLD J EMERG SURG 2019; 14: 27.
8. Reuken PA, Albig H, Rodel J, Hocke M, Will U, Stallmach A, Bruns T. Fungal Infections in Patients With Infected Pancreatic Necrosis and Pseudocysts: Risk Factors and Outcome. PANCREAS 2018; 47: 92-98.
9. Behrman SW, Bahr MH, Dickson PV, Zarzaur BL. The microbiology of secondary and postoperative pancreatic infections: implications for antimicrobial management. Arch Surg 2011; 146: 613-19.
10. Levine DP. Vancomycin: a history. CLIN INFECT DIS 2006; 42 Suppl 1: S5-12.
11. Bailie GR, Yu R, Morton R, Waldek S. Vancomycin, red neck syndrome, and fits. LANCET 1985; 2: 279-80.
12. Cole DR, Oliver M, Coward RA, Brown CB. Allergy, red man syndrome, and vancomycin. LANCET 1985; 2: 280.
13. Garrelts JC, Peterie JD. Vancomycin and the ”red man’s syndrome”. N Engl J Med 1985; 312: 245.
14. Bergman MM, Glew RH, Ebert TH. Acute interstitial nephritis associated with vancomycin therapy. Arch Intern Med 1988; 148: 2139-40.
15. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. AM J MED 1987; 83: 1091-97.
16. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-87.
17. Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DF. Mississippi Mud No More: Cost‐Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent Nephrotoxicity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2003; 23: 643-50.
18. Traber PG, Levine DP. Vancomycin Ototoxicity in patient with normal renal function. ANN INTERN MED 1981; 95: 458-60.
19. Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, Li DK, Liu YN, Yang KH, Zhang YY, Zhai SD. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. J Antimicrob Chemother 2016; 71: 3020-25.
20. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. AM J HEALTH-SYST PH 2020; 77: 835-64.
21. Burns GP, Stein TA, Kabnick LS. Blood-pancreatic juice barrier to antibiotic excretion. AM J SURG 1986; 151: 205-08.
22. Brattström C, Malmborg A, Tydén G. Penetration of Imipenem into Human Pancreatic Juice following Single Intravenous Dose Administration1. CHEMOTHERAPY 1989; 35: 83-87.
23. Wittau M, Wagner E, Kaever V, Koal T, Henne-Bruns D, Isenmann R. Intraabdominal tissue concentration of ertapenem. The Journal of antimicrobial chemotherapy 2006; 57: 312-16.
24. Schubert S, Dalhoff A. Activity of Moxifloxacin, Imipenem, and Ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in Monocultures and Mixed Cultures in an In Vitro Pharmacokinetic/Pharmacodynamic Model Simulating Concentrations in the Human Pancreas. ANTIMICROB AGENTS CH 2012; 56: 6434-36.
25. Wacke R, Forster S, Adam U, Mundkowski RG, Klar E, Hopt UT, Drewelow B. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J ANTIMICROB CHEMOTH 2006; 58: 994-99.
26. He N, Yan YY, Ying YQ, Yi M, Yao GQ, Ge QG, Zhai SD. [Individualized vancomycin dosing for a patient diagnosed as severe acute pancreatitis with concurrent extracorporeal membrane oxygenation and continuous veno-venous hemofiltration therapy: a case report]. Beijing Da Xue Xue Bao Yi Xue Ban 2018; 50: 915-20.
27. McConeghy KW, Liao S, Clark D, Worboys P, Barriere SL, Rodvold KA. Variability in telavancin cross-reactivity among vancomycin immunoassays. Antimicrob Agents Chemother 2014; 58: 7093-97.
28. Hooker AC, Staatz CE, Karlsson MO, Medicinska OFV, Institutionen FFB, Uppsala U, Avdelningen FFOL, Farmaceutiska F. Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE Method. PHARM RES-DORDR 2007; 24: 2187-97.
29. Ma N, Cui DJ, Lv GP, Deng Q. The penetration of antibiotics into the lung,liver,kidney and pancreas and their tissue bactericidal indexes. Tianjin Med J 2000; 28: 288-90.
30. M. Falconi PPGC. Facing the Pancreatic Dilemma: Springer Berlin Heidelberg, 1994.
31. He J, Mao E, Feng J, Jiang H, Yang W, Chen E. The pharmacokinetics of vancomycin in patients with severe acute pancreatitis. EUR J CLIN PHARMACOL 2016; 72: 697-702.
32. VANCOMYCIN. vancomycin injection, solution, Xellia Pharmaceuticals USA LLC.(2019).
Table1. Pharmacokinetic parameters estimated for vancomycin.